Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells

Biochemical Pharmacology

Volumn 65, Issue 12, 2003, Pages 1973-1978

  Scheiber Mojdehkar, Barbara ^a   Sturm, Brigitte ^a   Plank, Liane ^a   Kryzer, Ingrid ^a   Goldenberg, Hans ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ferritin; Ferrous iron transporter; Hepatoma cells; Labile iron pool; Non transferrin bound iron; Parenteral iron

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERRUM VITIS; IRON DEXTRAN; IRON REGULATORY FACTOR; IRON SACCHARATE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HEPATOMA CELL; HUMAN; HUMAN CELL; IRON METABOLISM; IRON TRANSPORT; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0038392370     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00181-3     Document Type: Article

References (35)

1. Sunder-Plassmann G., Horl W.H. Importance of iron supply for erythropoietin therapy. Nephrol. Dial. Transplant. 10:1995;2070-2076.
2. Besarab A., Kaiser J.W., Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am. J. Kidney Dis. 34:1999;21-28.
3. MacDougall I.C. Present and future strategies in the treatment of renal anemia. Nephrol. Dial. Trans. 16(suppl. 5):2001;50-55.
4. Atherton D.J., Cox I., Hann I. Intravenous iron(III) hydroxide-sucrose complex for anaemia in epidermolysis bullosa. Br. J. Dermatol. 140:1999;773.
5. Höchli P., Wagenhäuser F.J. Repeated continuous administration of low doses of i.v. iron in anemic patients with active rheumatoid arthritis. Eur. J. Haematol. 51:1993;54-55.
6. Martini A., Ravelli A., Di Fuccia G., Rosti V., Cazzola M., Barosi G. Intravenous iron therapy for severe anemia in systemic-onset juvenile chronic arthritis. Lancet. 344:1994;1052-1054.
7. Geisser P., Baer M., Schaub E. Structure/histotoxicity relationship of parenteral iron. Drug Res. 42:1992;1439-1452.
8. Sunder-Plassmann G., Horl W.H. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf. 17:1997;241-250.
9. Besarab A., Frinak S., Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J. Am. Soc. Nephrol. 10:1999;2029-2043.
10. Nissenson A.R., Lindsay R.M., Swan S., Seligman P., Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am. J. Kidney Dis. 33:1999;471-482.
11. Burns D.L., Pomposelli J.J. Toxicity of parenteral iron dextran therapy. Kidney Int. 55(suppl. 69):1999;S119-S124.
12. Zager R.A., Johnson A.C.M., Hanson S.Y., Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am. J. Kidney Dis. 40:2002;90-103.
13. Pascual J., Teruel J.L., Liano F., Sureda A., Ortuno J. Serious adverse reactions after intravenous ferric gluconate [letter]. Nephrol. Dial. Transplant. 7:1992;271-272.
14. Tovbin D., Mazor D., Vorobiov M., Chaimovitz C., Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am. J. Kidney Dis. 40:2002;1005-1012.
15. Bastani A.U., Jain A., Pandurangan G. Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. Nephroloy. 8:2003;8-10.
16. Kooistra M.P., van Es A., Struyvenberg A., Marx J.J. Iron metabolism in patients with the anemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br. J. Haematol. 79:1991;634-639.
17. Canavese C., Grill A., De Costanzi E., Martina G., Buglione E., Valente D., David O., Saitta M., Maddalena E., Barbieri S., Fop F., Salomone M., Piccoli G. How to save money for erythropoietin therapy by changing from 'Roller Coaster' to continuous iron supplementation. Nephron. 81:1999;362-363.
18. Danielson B.G., Salmonson T., Derendorf H., Geisser P. Pharmacokinetics of iron(III)-sucrose complex after a single intravenous dose in healthy volunteers. Drug. Res. 46:1996;615-621.
19. Beshara S., Lundqvist H., Sundin J., Lubberink M., Tolmachev V., Valind S., Antoni G., Langstrom B., Danielson B.G. Kinetic analysis of Fe-52-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography. Br. J. Haematol. 104:1999;288-295.
20. Rooyakkers T.M., Stroes E.S.G., Kooistra M.P., van Faassen E.E., Hider R.C., Rabelink T.J., Marx J.J.M. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur. J. Clin. Invest. 32(suppl. 1):2002;9-16.
21. Kuehn L.C., Hentze M.W. Coordination of cellular iron metabolism by post-transcriptional gene regulation. J. Inorg. Biochem. 47:1992;183-195.
22. Klausner R.D., Rouault T.A., Harford J.B. Regulating the fate of messenger RNA - the control of cellular iron metabolism. Cell. 72:1993;19-28.
23. Parkes J.G., Randell E.W., Olivieri N.F., Templeton D.M. Modulation by iron loading and chelation of the uptake of non-transferrin bound iron by human liver cells. Biochim. Biophys. Acta. 1243:1995;373-380.
24. Scheiber B., Zimmermann I., Dresow B., Goldenberg H. Differential response of non-transferrin bound iron uptake in rat liver cells on long-term and short term treatment with iron. J. Hepatol. 31:1999;61-70.
25. Amador E., Dorfmann L.E., Wacker W.E.C. Serum lactic dehydrogenase: an analytical assessment of current assays. Clin. Chem. 9:1963;391-395.
26. Müllner E.W., Neupert B., Kühn L.C. A specific messenger RNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor messenger RNA. Cell. 58:1989;373-382.
27. Müllner E.W., Rothenberger S., Müller A.M., Kühn L.C. In vivo and in vitro modulation of the mRNA-binding activity of iron-regulatory factor. Eur. J. Biochem. 208:1992;597-605.
28. Scheiber B., Goldenberg H. Uptake of iron by isolated rat hepatocytes from a hydrophilic impermeant ferric chelate, Fe(III)DTPA. Arch. Biochem. Biophys. 326:1996;185-192.
29. Scheiber B., Goldenberg H. The surface of rat hepatocytes can transfer iron from stable chelates to external acceptors. Hepatology. 27:1998;1075-1080.
30. Fleming M.D., Trenor C.C., Su M.A., Foernzler D., Beier D.R., Dietrich W.F., Andrews N.C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16:1997;383-386.
31. Fleming M.D., Romano M.A., Su M.A., Garrick L.M., Garrick M.D., Andrews N.C. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc. Natl. Acad. Sci. U.S.A. 95:1998;1148-1153.
32. Trinder D., Oates P.S., Thomas C., Sadleir J., Morgan E.H. Localisation of divalent metal transporter 1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload. GUT. 46:2000;270-276.
33. Lee P.L., Gelbart T., West C., Halloran C., Beutler E. The human Nramp2 gene: characterization of the gene structure, alternative splicing, promoter region and polymorphisms. Blood Cells Mol. Dis. 24:1998;199-215.
34. Hagen K., Zhu C., Melefors O., Hultcrantz R. Susceptibility of cultured rat hepatocytes to oxidative stress by peroxides and iron. The extracellular matrix affects the toxicity of tert-butyl hydroperoxide. Int. J. Biochem. Mol. Biol. 31:1999;499-508.
35. Staeubli A., Boelsterli U.A. The labile iron pool in hepatocytes: prooxidant-induced increase in free iron precedes oxidative cell injury. Am. J. Physiol. 274:1998;G1031-G1037.